Modality
Vaccine
MOA
Anti-Aβ
Target
CGRP
Pathway
Notch
MCLGISTBCC
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Jan 2030
Phase 1Current
NCT07149478
2,292 pts·GIST
2018-01→2030-01·Recruiting
NCT07864790
1,416 pts·MCL
2018-02→2027-08·Recruiting
3,708 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-271.4y awayInterim· MCL
2030-01-193.8y awayInterim· GIST
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2027-08-27 · 1.4y away
MCL
Interim
2030-01-19 · 3.8y away
GIST
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07149478 | Phase 1 | GIST | Recruiting | 2292 | SRI-4 |
| NCT07864790 | Phase 1 | MCL | Recruiting | 1416 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT |